INTERVIEW: New CEO to push Avita out of stagnation
This article was originally published in Clinica
Executive Summary
Avita Medical Ltd, which has been incubating its ReCell skin regeneration technology for more than 20 years, is now close to seeing the therapy put to the wide-scale use it was intended for - helping victims of burns and other wounds grow back their skin quickly without significant scarring. This is thanks to a new $54m contract the Australian-listed company has secured with the US government.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.